Evidence map›Paper›PMID 34786276›Full record

ArticleCureus2021

Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve.

Andrea Messori

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Shared genetic association between inflammatory bowel disease and acute myeloid leukemia: insights from mendelian randomization and transcriptomic analyses.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Andrea MessoriHealth Technology Assessment (HTA) Unit, Regione Toscana, Firenze, ITA.
Agenzia Regionale di Sanità della Toscana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction In conducting a survival meta-analysis, the typical methodological approach analyses the hazard ratios (HRs) of individual trials and then combines them into a pooled meta-analytical estimate. The length of follow-up of individual trials is not generally accounted for. Recent techniques aimed at individual patient-data reconstruction from Kaplan-Meier graphs represent an important methodological innovation. These techniques permit the combination of the survival curves published in a single clinical trial but are also applicable to more than one trial. In the case of multiple trials, a meta-analysis can be conducted without using any statistical model of meta-analysis. Methods As an example of this new approach, we applied a technique of individual patient data reconstruction to the Kaplan-Meier graphs of overall survival reported in two phase-III trials, which were conducted on patients with locally advanced/advanced non-small cell lung cancer selected according to their PD-L1 expression status, not previously treated for their metastatic disease. Only subjects with PD-L1 ≥50% were considered for our analysis. The experimental arms received pembrolizumab monotherapy while the control arms were given platinum-based chemotherapy. The survival graphs were obtained for both trials. For each Kaplan-Meier curve, the graph was firstly digitalized. Then, the Shiny package was used to reconstruct patient-level data. Finally, the pooled survival curves were generated from the reconstructed patient-level data along with the relevant Cox statistics; for this purpose, we used three packages ("coxph", "survfit", and "ggsurvplot") under the R-platform. Results In our pooled analysis based on this procedure, we compared 453 patients given pembrolizumab vs. 451 controls given chemotherapy. The HR estimated from reconstructed patient-level data was 0.670 (95% confidence interval [CI], 0.566 to 0.793). Conclusion The analysis described herein demonstrates the easy applicability of the Shiny technique. This technique was successful in generating a pooled survival graph for the experimental treatment groups vs. controls and efficiently estimated the pooled HR in which the results of the two trials were combined.

Indexed as

immune checkpoint inhibitorsindividual-patient datakaplan-meier survival curvesmeta-analysisreconstruction of patient-level data

Identifiers

PMID34786276
PMCPMC8578838
OpenAlexW3213454691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.